NASDAQ:HRTX - Heron Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $25.33
  • Forecasted Upside: 109.37 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$12.10
▲ +0.33 (2.80%)

This chart shows the closing price for HRTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Heron Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HRTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HRTX

Analyst Price Target is $25.33
▲ +109.37% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Heron Therapeutics in the last 3 months. The average price target is $25.33, with a high forecast of $27.00 and a low forecast of $24.00. The average price target represents a 109.37% upside from the last price of $12.10.

This chart shows the closing price for HRTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Heron Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/20/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/23/2021Jefferies Financial GroupReiterated RatingBuy$25.00Medium
5/13/2021Stifel NicolausReiterated RatingBuy$27.00High
12/2/2020SVB LeerinkBoost Price TargetOutperform$21.00 ➝ $24.00Medium
9/8/2020Stifel NicolausReiterated RatingBuyMedium
8/6/2020Northland SecuritiesInitiated CoverageBuy$35.00Medium
8/6/2020Stifel NicolausReiterated RatingBuy$21.00Medium
6/30/2020SVB LeerinkLower Price TargetOutperform$26.00 ➝ $19.00Low
6/29/2020Stifel NicolausInitiated CoverageBuy$21.00Medium
6/22/2020Northland SecuritiesInitiated CoverageBuy$47.00High
5/26/2020GuggenheimInitiated CoverageBuy$24.00Medium
5/18/2020FIXInitiated CoverageAddLow
5/6/2020Stifel NicolausReiterated RatingBuy$29.00Medium
4/15/2020Needham & Company LLCReiterated RatingBuy$44.00High
3/2/2020Stifel NicolausReiterated RatingBuy$29.00Low
3/2/2020Needham & Company LLCLower Price TargetBuy$48.00 ➝ $44.00High
2/20/2020Cantor FitzgeraldReiterated RatingBuy$41.00N/A
2/20/2020Needham & Company LLCLower Price TargetBuy$50.00 ➝ $48.00High
1/15/2020CowenReiterated RatingBuy$40.00Low
11/13/2019Northland SecuritiesReiterated RatingBuy$47.00High
11/12/2019SVB LeerinkReiterated RatingOutperformMedium
10/3/2019JMP SecuritiesLower Price TargetOutperform ➝ Market Outperform$38.00 ➝ $32.00High
10/1/2019JMP SecuritiesReiterated RatingOutperform$33.00 ➝ $38.00High
10/1/2019CowenReiterated RatingBuy$40.00High
8/13/2019Evercore ISIReiterated RatingBuy$75.00Low
8/5/2019Stifel NicolausReiterated RatingBuy$38.00Low
8/5/2019Northland SecuritiesReiterated RatingBuy$55.00Low
5/9/2019CowenReiterated RatingBuyMedium
5/9/2019Northland SecuritiesReiterated RatingBuy$55.00High
5/1/2019Stifel NicolausReiterated RatingBuy$38.00High
4/2/2019Northland SecuritiesSet Price TargetBuy$55.00High
3/11/2019Northland SecuritiesReiterated RatingBuyMedium
3/4/2019Cantor FitzgeraldDowngradeOverweight ➝ NeutralHigh
2/22/2019Cantor FitzgeraldSet Price TargetBuy$50.00High
2/22/2019Stifel NicolausReiterated RatingBuy$54.00Low
1/16/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$66.00 ➝ $64.00Medium
12/31/2018Cantor FitzgeraldReiterated RatingBuy$50.00High
10/30/2018Cantor FitzgeraldSet Price TargetBuy$50.00Medium
9/27/2018Cantor FitzgeraldSet Price TargetBuy$50.00High
9/21/2018Cantor FitzgeraldSet Price TargetBuy$50.00High
9/13/2018Stifel NicolausInitiated CoverageBuy$55.00Low
8/8/2018Cantor FitzgeraldReiterated RatingBuy$50.00Low
7/19/2018Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$40.00 ➝ $50.00High
6/22/2018OppenheimerBoost Price TargetOutperform ➝ Outperform$34.00 ➝ $50.00Medium
6/22/2018SVB LeerinkBoost Price TargetOutperform$46.00High
6/22/2018MizuhoReiterated RatingBuy$41.00High
6/21/2018CowenReiterated RatingBuy$54.00High
6/21/2018Needham & Company LLCBoost Price TargetBuy ➝ Positive$66.00Medium
6/21/2018Cantor FitzgeraldReiterated RatingBuy$40.00High
6/21/2018Evercore ISIBoost Price TargetOutperform$56.00 ➝ $80.00High
5/24/2018Cantor FitzgeraldSet Price TargetBuy$40.00Medium
5/10/2018OppenheimerSet Price TargetBuy$34.00High
5/10/2018Cantor FitzgeraldSet Price TargetBuy$40.00Medium
5/8/2018CowenReiterated RatingBuy$48.00Low
4/22/2018Cantor FitzgeraldSet Price TargetBuy$40.00Medium
4/6/2018Cantor FitzgeraldSet Price TargetBuy$40.00Low
4/5/2018Evercore ISIInitiated CoverageOutperform$56.00Medium
4/5/2018Lake Street CapitalSet Price TargetBuy$42.00Medium
3/27/2018OppenheimerSet Price TargetBuy$34.00Low
3/26/2018Northland SecuritiesReiterated RatingBuy$55.00Low
3/21/2018Noble FinancialReiterated RatingBuyLow
3/20/2018Needham & Company LLCBoost Price TargetBuy$42.00Medium
3/19/2018CowenReiterated RatingBuyMedium
3/19/2018OppenheimerSet Price TargetBuy$34.00Low
3/19/2018MizuhoReiterated RatingBuy ➝ Buy$28.00 ➝ $35.00High
3/19/2018Cantor FitzgeraldSet Price TargetBuy$40.00Medium
3/2/2018Noble FinancialReiterated RatingBuyHigh
3/1/2018OppenheimerSet Price TargetBuy$27.00Low
3/1/2018Needham & Company LLCReiterated RatingBuy ➝ Buy$28.00 ➝ $30.00High
2/27/2018Cantor FitzgeraldSet Price TargetBuy$31.00High
2/16/2018Lake Street CapitalSet Price TargetBuy$42.00Low
2/15/2018Cantor FitzgeraldSet Price TargetBuy$31.00Low
1/16/2018MizuhoReiterated RatingBuy$28.00Low
1/15/2018Cantor FitzgeraldSet Price TargetBuy$31.00Low
1/5/2018Cantor FitzgeraldSet Price TargetBuy$31.00Low
1/2/2018SVB LeerinkInitiated CoverageOutperform ➝ Outperform$22.00High
12/14/2017OppenheimerSet Price TargetBuy$27.00Low
12/8/2017MizuhoReiterated RatingBuy$28.00Medium
12/6/2017CowenReiterated RatingBuy$40.00Medium
11/12/2017Noble FinancialReiterated RatingBuyN/A
11/10/2017OppenheimerReiterated RatingBuy$27.00N/A
11/7/2017MizuhoReiterated RatingBuy$28.00N/A
11/6/2017CowenReiterated RatingBuy$40.00N/A
11/2/2017Cantor FitzgeraldReiterated RatingBuy$31.00N/A
10/30/2017OppenheimerInitiated CoverageBuy$27.00N/A
10/26/2017Cantor FitzgeraldSet Price TargetBuy$31.00N/A
10/20/2017Cantor FitzgeraldSet Price TargetBuy$31.00N/A
10/6/2017Noble FinancialReiterated RatingBuy$24.00N/A
9/27/2017Northland SecuritiesInitiated CoverageOutperform ➝ Outperform$40.00Low
9/26/2017MizuhoInitiated CoverageBuy$28.00Low
9/25/2017Cantor FitzgeraldReiterated RatingBuyMedium
8/18/2017Cantor FitzgeraldSet Price TargetBuy$31.00Low
8/16/2017Jefferies Financial GroupReiterated RatingBuyLow
8/10/2017Noble FinancialReiterated RatingBuyHigh
8/3/2017CowenSet Price TargetBuy$40.00Low
7/18/2017AegisReiterated RatingBuy$33.00Low
7/14/2017Jefferies Financial GroupReiterated RatingBuy$26.00Low
6/26/2017Cantor FitzgeraldReiterated RatingOverweightHigh
5/26/2017CowenReiterated RatingBuy$40.00High
5/12/2017Noble FinancialReiterated RatingBuyMedium
5/11/2017Cantor FitzgeraldReiterated RatingBuy$30.00 ➝ $31.00Medium
4/10/2017Jefferies Financial GroupReiterated RatingBuy$29.00Low
3/21/2017AegisReiterated RatingBuyMedium
2/27/2017Needham & Company LLCInitiated CoverageBuy ➝ Buy$28.00N/A
2/26/2017Cantor FitzgeraldSet Price TargetBuy$34.00 ➝ $30.00N/A
1/12/2017Cantor FitzgeraldSet Price TargetBuy$34.00N/A
1/6/2017Cantor FitzgeraldReiterated RatingOverweight$34.00N/A
1/6/2017CowenReiterated RatingBuy$40.00N/A
1/5/2017Jefferies Financial GroupSet Price TargetBuy$40.00 ➝ $29.00N/A
1/5/2017SVB LeerinkSet Price TargetBuy$21.00N/A
12/11/2016CowenReiterated RatingBuy$40.00N/A
11/10/2016Cantor FitzgeraldReiterated RatingBuy$34.00N/A
11/9/2016JMP SecuritiesReiterated RatingBuyN/A
10/26/2016AegisInitiated CoverageBuy$41.00N/A
10/8/2016SVB LeerinkSet Price TargetBuy$34.00N/A
10/4/2016Brean CapitalInitiated CoverageBuy$41.00N/A
10/3/2016Jefferies Financial GroupLower Price TargetBuy$46.00 ➝ $40.00N/A
10/2/2016SVB LeerinkReiterated RatingBuy$33.00N/A
(Data available from 9/19/2016 forward)

News Sentiment Rating

0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/23/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/21/2021
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/21/2021
  • 3 very positive mentions
  • 2 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
8/20/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
9/19/2021

Current Sentiment

  • 1 very positive mentions
  • 0 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

Heron Therapeutics logo
Heron Therapeutics, Inc. is a biotechnology company, which engages in the development of pharmaceutical products for patients suffering from cancer. Its products portfolio include SUSTOL, Cinvanti, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $12.10
Low: $11.54
High: $12.13

50 Day Range

MA: $11.92
Low: $10.13
High: $13.67

52 Week Range

Now: $12.10
Low: $10.10
High: $22.40

Volume

2,606,389 shs

Average Volume

1,335,880 shs

Market Capitalization

$1.23 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.39

Frequently Asked Questions

What sell-side analysts currently cover shares of Heron Therapeutics?

The following Wall Street research analysts have issued research reports on Heron Therapeutics in the last twelve months: Jefferies Financial Group Inc., Stifel Nicolaus, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for HRTX.

What is the current price target for Heron Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Heron Therapeutics in the last year. Their average twelve-month price target is $25.33, suggesting a possible upside of 109.4%. Stifel Nicolaus has the highest price target set, predicting HRTX will reach $27.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $24.00 for Heron Therapeutics in the next year.
View the latest price targets for HRTX.

What is the current consensus analyst rating for Heron Therapeutics?

Heron Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HRTX will outperform the market and that investors should add to their positions of Heron Therapeutics.
View the latest ratings for HRTX.

What other companies compete with Heron Therapeutics?

How do I contact Heron Therapeutics' investor relations team?

Heron Therapeutics' physical mailing address is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company's listed phone number is (858) 251-4400 and its investor relations email address is [email protected] The official website for Heron Therapeutics is www.herontx.com.